全文获取类型
收费全文 | 2352篇 |
免费 | 227篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 88篇 |
妇产科学 | 42篇 |
基础医学 | 296篇 |
口腔科学 | 81篇 |
临床医学 | 179篇 |
内科学 | 493篇 |
皮肤病学 | 19篇 |
神经病学 | 217篇 |
特种医学 | 72篇 |
外科学 | 267篇 |
综合类 | 169篇 |
现状与发展 | 1篇 |
一般理论 | 3篇 |
预防医学 | 162篇 |
眼科学 | 49篇 |
药学 | 239篇 |
2篇 | |
中国医学 | 9篇 |
肿瘤学 | 162篇 |
出版年
2023年 | 17篇 |
2022年 | 41篇 |
2021年 | 67篇 |
2020年 | 37篇 |
2019年 | 64篇 |
2018年 | 67篇 |
2017年 | 29篇 |
2016年 | 47篇 |
2015年 | 58篇 |
2014年 | 80篇 |
2013年 | 106篇 |
2012年 | 135篇 |
2011年 | 126篇 |
2010年 | 75篇 |
2009年 | 58篇 |
2008年 | 100篇 |
2007年 | 133篇 |
2006年 | 106篇 |
2005年 | 97篇 |
2004年 | 100篇 |
2003年 | 79篇 |
2002年 | 75篇 |
2001年 | 67篇 |
2000年 | 63篇 |
1999年 | 48篇 |
1998年 | 21篇 |
1997年 | 20篇 |
1996年 | 21篇 |
1993年 | 15篇 |
1992年 | 49篇 |
1991年 | 34篇 |
1990年 | 29篇 |
1989年 | 39篇 |
1988年 | 30篇 |
1987年 | 23篇 |
1986年 | 18篇 |
1985年 | 27篇 |
1984年 | 26篇 |
1983年 | 23篇 |
1981年 | 17篇 |
1980年 | 19篇 |
1979年 | 30篇 |
1978年 | 20篇 |
1977年 | 28篇 |
1976年 | 16篇 |
1975年 | 17篇 |
1973年 | 32篇 |
1972年 | 16篇 |
1971年 | 20篇 |
1970年 | 20篇 |
排序方式: 共有2582条查询结果,搜索用时 31 毫秒
61.
62.
63.
Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation
Wong AM Allen JC Goh YT Linn YC Loh SM Diong CP Chowbay B Hwang WY 《Bone marrow transplantation》2012,47(2):181-189
We performed a single institution retrospective analysis of 114 patients treated with BU-based pretransplant conditioning regimens. Oral BU was administered to 76 patients (total dose 16?mg/kg or 8?mg/kg) and i.v. BU to 38 others (total dose 12.8?mg/kg or 6.4?mg/kg). Either CY (n=74) or fludarabine (n=40) was given in combination with BU. Median age was 35 years in the oral BU group and 48.5 years with i.v. BU (P<0.001). OS and PFS rates at 3-years post HSCT were not different in patients who received either i.v. or oral BU (OS: 41.3 vs 44.0% (P=0.981); PFS: 52.7 vs 54.7% (P=0.526), respectively). The i.v. BU, however, was associated with a significantly shorter time to engraftment (13.5 days vs 16 days, respectively; P<0.001). There were no significant differences in survival or 100-day mortality for patients who received either CY or fludarabine, in combination with BU. After adjustment for confounders, multivariate analysis showed that age of transplant (P=0.002), donor type (sibling or unrelated; P=0.003), GVHD (P<0.05) and route of administration (P=0.023) were significant risk factors for OS. The i.v. BU used in an older age group yielded equivalent survival compared with oral BU used in a younger population. 相似文献
64.
65.
66.
A previously healthy 20‐year‐old man presented with adult Still disease (ASD). He developed life‐threatening macrophage activation syndrome (MAS), which was refractory to standard immunosuppression but responded dramatically to the IL‐1 receptor antagonist anakinra. Subsequent immunological investigations included assessment of the perforin expression of natural killer (NK) cells and CD8+ T cells, which confirmed MAS. 相似文献
67.
Swati Mehta Katherine Orenczuk Amanda McIntyre Gabrielle Willems Dalton L. Wolfe Jane T. C. Hsieh Christine Short Eldon Loh Robert W. Teasell SCIRE Research Team 《Topics in spinal cord injury rehabilitation》2013,19(1):78-86
Background:
Pharmacotherapy may not sufficiently reduce neuropathic pain in many individuals post spinal cord injury (SCI). The use of alternative therapies such as surgery may be effective in reducing neuropathic pain in these individuals. However, because of the invasive nature of surgery, it is important to examine the evidence for use of this treatment.Objective:
The purpose of this study was to conduct a systematic review of published literature on the surgical treatment of neuropathic pain after SCI.Methods:
MEDLINE, CINAHL, EMBASE, and PsycINFO databases were searched for articles in which surgical treatment of pain after SCI was examined. Articles were restricted to the English language. Article selection was conducted by 2 independent reviewers with the following inclusion criteria: the subjects participated in a surgical intervention for neuropathic pain; at least 50% of the subjects had an SCI; at least 3 subjects had an SCI; and a definable intervention involving the dorsal root entry zone (DREZ) procedure was used to reduce pain. Data extracted included study design, study type, subject demographics, inclusion and exclusion criteria, sample size, outcome measures, and study results. Randomized controlled trials (RCTs) were assessed for quality using the Physiotherapy Evidence Database (PEDro) assessment scale. Levels of evidence were assigned to each intervention using a modified Sackett scale.Results:
Eleven studies met the inclusion criteria. One study provided level 2 evidence, and the rest provided level 4 evidence. The DREZ procedure was shown to be more effective for segmental pain than for diffuse pain after SCI. Further, individuals with conus medullaris level injury were found to have a higher level of neuropathic pain relief than those with cervical, thoracic, or cauda equina injury.Conclusions:
The studies demonstrated that the DREZ procedure may be effective in reducing segmental pain. Hence, DREZ may be important in treatment of neuropathic pain in individuals resistant to less invasive treatments. Because the studies lacked control conditions and examination of long-term effects, there is a need for larger trials with more stringent conditions.Key words: pain, spinal cord injury, surgical treatmentPain is a major cause of distress and disability in persons with spinal cord injury (SCI). It has been shown to lead to social isolation, unemployment, decreased function, decreased quality of life, depression, and even suicide.1,2 More than 77% of individuals with an SCI indicated that pain interfered with one or more of their daily activities including sleep (40%), exercise (34.9%), and work (33.6%).2 The International Association for the Study of Pain (IASP) defines neuropathic pain as “pain caused by a lesion or disease of the somatosensory nervous system.”3 After an SCI, individuals often report the onset of chronic neuropathic pain caudal to the level of the lesion or at the same level within the associated spinal cord segment.4 Dijkers et al5 reported no difference in the prevalence of pain based on level or completeness.The reported incidence of neuropathic pain after SCI varies greatly among studies, but between 10% and 30% of patients with SCI experience pain severe enough to interfere with their activities of daily living6,7 and may require surgical intervention to relieve persistent and refractory pain.4,8 Unmanageable neuropathic pain occurs more often in individuals with conus medullaris and cauda equina lesions where damage also involves the peripheral nerve roots.8When pharmacological and other noninvasive treatments fail to reduce pain, surgical spinal cord stimulation and dorsal root entry zone (DREZ) ablation treatments, such as DREZ lesioning and microsurgical DREZotomy (MDT), can be considered as options for the management of refractory pain.9 Neurosurgical procedures to reduce neuropathic pain should be reserved for cases in which medical therapies have failed to sufficiently reduce pain.4 The risks associated with ablative surgeries can be significant for individuals with incomplete neurological deficits; therefore, DREZ ablation is generally only considered a treatment option when neuropathic pain is present after a complete SCI.8 The MDT procedure targets for ablation the nociceptive fibers in the lateral bundle of the dorsal rootlet, the deafferented neurons of the dorsal horn, and the medial portion of the Lissauer tract.4,6 This systematic review was conducted to assess the effectiveness of DREZ ablation therapies in reducing neuropathic pain in individuals following SCI. 相似文献68.
69.
Sanskriti Sasikumar MD Melanie Cohn PhD Irene E. Harmsen BSc Aaron Loh MB BCh BAO Sang Soo Cho PhD Michel Sáenz-Farret MD MSc Ricardo Maciel MD MSc Derrick Soh MD Alexandre Boutet MD PhD Jürgen Germann PhD Gavin Elias BA Ariana Youm MA Katherine Duncan PhD Nathan C. Rowland MD PhD Antonio P. Strafella MD PhD Suneil K. Kalia MD PhD Andres M. Lozano MD PhD Alfonso Fasano MD PhD 《Movement disorders》2022,37(3):635-640
70.